PURPOSE: Systemic lupus erythematous (SLE) is a systemic autoimmune inflammatory disease with both genetic and epigenetic etiologies. Evidence suggests that deregulation of specific genes through epigenetic mechanisms may be a contributing factor to SLE pathology. There is increasing evidence that DNA methyltransferase activity may be involved. This study demonstrated modulation in expression of DNA methyltransferases (DNMTs) according to ethnicity in patients diagnosed with SLE. Furthermore, differential expression in one of the DNMTs was found in a subset of lupus patients on dehydroepiandrosterone (DHEA) therapy. METHODS: Real-time PCR analyses of DNMT1, DNMT3A and DNMT3B in peripheral blood mononuclear cells from a cohort of African American and European American lupus and non-lupus women were conducted. Also, global DNA methylation was assessed using the MethylFlash(TM) methylated quantification colorimetric assay. RESULTS: Significant increase in DNMT3A (p < 0.001) was shown in lupus patients when compared to age-matched healthy controls. This increase was associated with a higher SLEDI index. More striking was that expression levels for African American (AA) women were higher than European American women in the lupus populations. A subset of AA women on DHEA therapy showed a significant decrease (p < 0.05) in DNMT3A expression in comparison to lupus patients not on the therapy. DHEA is an androgenic steroid found in low levels in the serum of lupus patients. Supplementation of this hormone has been shown to be beneficial to some lupus patients. DHEA was not shown to effect DNMT1 or DNMT3B expression. Increased expression was also noted in DNMT3B (p < 0.05) in lupus patients compared to age-matched healthy controls. However, no significant difference was noted in DNMT1 (p = 0.2148) expression between lupus patients and healthy controls. Although increases were detected in de novo methyltransferases, a global decrease (p < 0.001) in 5-methycytosine was observed in lupus patients when compared to age-matched healthy controls. CONCLUSION: These findings suggest that epigenetic changes may play a critical role in the manifestations of the disease observed among ethnic groups, particularly African American women who often have a higher incidence of lupus. DHEA therapy effects on DNMT3A expression in AA women warrant further investigation in a larger population.
PURPOSE:Systemic lupus erythematous (SLE) is a systemic autoimmune inflammatory disease with both genetic and epigenetic etiologies. Evidence suggests that deregulation of specific genes through epigenetic mechanisms may be a contributing factor to SLE pathology. There is increasing evidence that DNA methyltransferase activity may be involved. This study demonstrated modulation in expression of DNA methyltransferases (DNMTs) according to ethnicity in patients diagnosed with SLE. Furthermore, differential expression in one of the DNMTs was found in a subset of lupuspatients on dehydroepiandrosterone (DHEA) therapy. METHODS: Real-time PCR analyses of DNMT1, DNMT3A and DNMT3B in peripheral blood mononuclear cells from a cohort of African American and European American lupus and non-lupuswomen were conducted. Also, global DNA methylation was assessed using the MethylFlash(TM) methylated quantification colorimetric assay. RESULTS: Significant increase in DNMT3A (p < 0.001) was shown in lupuspatients when compared to age-matched healthy controls. This increase was associated with a higher SLEDI index. More striking was that expression levels for African American (AA) women were higher than European American women in the lupus populations. A subset of AA women on DHEA therapy showed a significant decrease (p < 0.05) in DNMT3A expression in comparison to lupuspatients not on the therapy. DHEA is an androgenic steroid found in low levels in the serum of lupuspatients. Supplementation of this hormone has been shown to be beneficial to some lupuspatients. DHEA was not shown to effect DNMT1 or DNMT3B expression. Increased expression was also noted in DNMT3B (p < 0.05) in lupuspatients compared to age-matched healthy controls. However, no significant difference was noted in DNMT1 (p = 0.2148) expression between lupuspatients and healthy controls. Although increases were detected in de novo methyltransferases, a global decrease (p < 0.001) in 5-methycytosine was observed in lupuspatients when compared to age-matched healthy controls. CONCLUSION: These findings suggest that epigenetic changes may play a critical role in the manifestations of the disease observed among ethnic groups, particularly African American women who often have a higher incidence of lupus. DHEA therapy effects on DNMT3A expression in AA women warrant further investigation in a larger population.
Authors: M Cristina Kenney; Marilyn Chwa; Shari R Atilano; Payam Falatoonzadeh; Claudio Ramirez; Deepika Malik; Mohamed Tarek; Javier Cáceres Del Carpio; Anthony B Nesburn; David S Boyer; Baruch D Kuppermann; Marquis P Vawter; S Michal Jazwinski; Michael V Miceli; Douglas C Wallace; Nitin Udar Journal: Biochim Biophys Acta Date: 2013-11-04
Authors: Carolina Hurtado; Diego Fernando Rojas-Gualdrón; Rodrigo Urrego; Kevin Cashman; Elsa María Vásquez-Trespalacios; Juan Camilo Díaz-Coronado; Mauricio Rojas; Scott Jenks; Gloria Vásquez; Ignacio Sanz Journal: Front Med (Lausanne) Date: 2022-09-06
Authors: Anna Gillio-Tos; Maria da Graça Bicalho; Valentina Fiano; Chiara Grasso; Valentina Tarallo; Laura De Marco; Morena Trevisan; Marinabarbaradesousa Xavier; Renata Slowik; Newton S Carvalho; Carlos A Maestri; Hadriano M Lacerda; Daniela Zugna; Lorenzo Richiardi; Franco Merletti Journal: BMC Cancer Date: 2012-12-24 Impact factor: 4.430
Authors: Edward L Treadwell; Kenneth Wiley; Beverly Word; William Melchior; William H Tolleson; Neera Gopee; George Hammons; Beverly D Lyn-Cook Journal: J Immunol Res Date: 2015-10-25 Impact factor: 4.818
Authors: Ismael Khouly; Simon Pardiñas López; Silvia María Díaz Prado; Luca Ferrantino; Josephine Kalm; Lena Larsson; Farah Asa'ad Journal: Int J Environ Res Public Health Date: 2022-01-17 Impact factor: 3.390